专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003074484A1 INDOLAMID DERIVATIVES WHICH POSSESS GLYCOGENPHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有抗坏血酸酶抑制活性的吲哚胺衍生物
公开(公告)号：WO2003074484A1
公开(公告)日：2003-09-12
申请号：PCT/GB2003/000883
申请日：2003-03-04
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , WHITTAMORE, Paul, Robert, Owen , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
发明人： WHITTAMORE, Paul, Robert, Owen , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
IPC分类号： C07D209/42
CPC分类号： C07D401/12 , C07D209/42 , C07D403/12 , C07D409/12 , C07D413/12
摘要： Heterocyclic amides of formula (1) wherein: is a single or double bond;A is phenylene or heteroarylene;m is 0, 1 or 2;n is 0, 1 or 2;R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR 2 R 3 or -OR 3 ;R 2 and R 3 are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups);R 4 is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, -COCOOR 9 , -C(O)N(R 9 )(R 10 ), -NHC(O)R 9 , (R 9 )(R 10 )N- and -COOR 9 ;R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 );R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy;or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的杂环酰胺其中：是单键或双键; A是亚苯基或亚杂芳基; m是0,1或2; n是0,1或2; R 1选自例如卤素，硝基，氰基，羟基，羧基; r为1或2; Y是-NR 2 R 3或-OR 3; R 2和R 3选自例如氢，羟基，芳基，杂环基和C 1-4烷基（任选被1或2个R 8基团取代）; R 4选自例如氢，硝基，氰基，羟基，C 1-4烷基和C 1-4烷酰基; R8选自例如羟基，-COCOOR9，-C（O）N（R9）（R10），-NHC（O）R9，（R9）（R10）N-和-COOR9; R9和R10选自例如氢，羟基，C 1-4烷基（任选被1或2个R 13取代）; R 13选自羟基，卤素，三卤代甲基和C 1-4烷氧基;或其药学上可接受的盐或前体药物; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

2. 发明申请

WO2003074531A1 HETEROCYCLIC AMIDE DERIVATIVES HAVING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有GLYCOGEN PHOSPHORYLASE抑制活性的杂环酰胺衍生物
公开(公告)号：WO2003074531A1
公开(公告)日：2003-09-12
申请号：PCT/GB2003/000875
申请日：2003-03-04
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , WHITTAMORE, Paul, Robert, Owen , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
发明人： WHITTAMORE, Paul, Robert, Owen , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
IPC分类号： C07D495/04
CPC分类号： C07D495/04
摘要： Heterocyclic amides of formula (1) wherein: Z is CH or nitrogen; R 4 and R 5 together are either -S-C(R 6 )=C(R 7 )- or -C(R 7 )=C(R 6 )-S- ; R 6 and R7 are selected from for example hydrogen, halo, C 1-4 alkyl, and C 1-4 alkanoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR 2 R 3 or -OR 3 ; R 2 and R 3 are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl (optionally substituted by 1 or 2 R 8 groups); R 4 is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, -COCOOR 9 , -C(O)N(R 9 )(R 10 ), -NHC(O)R 9 , (R 9 )(R 10 )N- and -COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的杂环酰胺其中：Z是CH或氮; R4和R5一起是-S-C（R6）= C（R7） - 或-C（R7）= C（R6）-S-; R 6和R 7选自例如氢，卤素，C 1-4烷基和C 1-4烷酰基; A是亚苯基或亚杂芳基; n为0,1或2; R 1选自例如卤素，硝基，氰基，羟基，羧基; r为1或2; Y是-NR2R3或-OR3; R2和R3选自例如氢，羟基，芳基，杂环基和C 1-4烷基（任选被1或2个R 8基团取代）; R4选自例如氢，卤素，硝基，氰基，羟基，C 1-4烷基和C 1-4烷酰基; R8选自例如羟基，-COCOOR9，-C（O）N（R9）（R10），-NHC（O）R9，（R9）（R10）N-和-COOR9; R9和R10选自例如氢，羟基，C 1-4烷基（任选被1或2个R 13取代）; R 13选自羟基，卤代，三卤代甲基和C 1-4烷氧基; 或其药学上可接受的盐或前体药物; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。

3. 发明申请

WO2005020986A1 HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：含有羟基磷酸酶抑制活性的杂环酰胺衍生物
公开(公告)号：WO2005020986A1
公开(公告)日：2005-03-10
申请号：PCT/GB2004/003622
申请日：2004-08-25
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
发明人： BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
IPC分类号： A61K31/407
CPC分类号： C07D495/04
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt thereof wherein: R 4 and R 5 together are either -S-C(R 6 )=C(R 7 )- or -C(R 7 )=C(R 6 )-S-; A is phenylene or heteroarylene; R 1 is for example selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, N -(1-4C)alkylcarbamoyl, N -(1-4C)alkylsulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, and -NHSO 2 (1-4C)alkyl; or, when n is 2, the two R 1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from O, S and N; R 2 and R 3 together with the nitrogen to which they are attached form an optionally substituted 4- to 7-membered, heterocyclic ring; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐，其中：R 4和R 5一起是-SC（R 6）= C（R 7） - 或-C（ [R <7>）= C（R <6>） - S-; A是亚苯基或亚杂芳基; R 1选自卤素，硝基，氰基，羟基，羧基，氨基甲酰基，N-（1-4C）烷基氨基甲酰基，N-（1-4C）烷基氨磺酰基，（1-4C）烷基，（1-4C ）烷氧基，（1-4C）烷酰基，（1-4C）烷酰氧基，羟基（1-4C）烷基，氟甲基和-NHSO2（1-4C）烷基; 或者当n为2时，两个R 1基团与它们所连接的A的碳原子一起可以形成4至7元饱和环，任选地含有1或2个独立地选自O，S的杂原子和N; R 2和R 3与它们所连接的氮一起形成任选取代的4-至7-元杂环; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备含有它们的化合物和药物组合物的方法。

4. 发明申请

WO2005018637A1 HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：杂环化合物酰胺衍生物，其具有磷酸酶抑制活性
公开(公告)号：WO2005018637A1
公开(公告)日：2005-03-03
申请号：PCT/GB2004/003546
申请日：2004-08-18
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
发明人： BENNETT, Stuart, Norman, Lile , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
IPC分类号： A61K31/407
CPC分类号： C07D495/04
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: R 4 and R 5 together are either -S-C(R 6 =C(R 7 )- or -C(R 7 )=C(R 6 )-S- ; R 6 and R 7 are independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is halo, cyano or carboxy; R 2 is for example methyl; R 3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐或其前体药物; （1）其中例如：R 4和R 5一起是-SC（R 6 = C（R 7） - 或-C（R 7）= C（R' 6）） - S-; R 6和R 7独立地选自氢和卤素; A是亚苯基或亚杂芳基; n是0,1或2; R 1是卤素，氰基或羧基; R 2是例如甲基; R 3例如选自卤素（1-4C）烷基，二卤代（1-4C）烷基，三氟甲基，羟基（1-4C）烷基，二羟基（2-4C）烷基，（1-4C）烷基，（1-4C）烷基，（1-4C）烷氧基（1-4C）烷基，（1-4C）烷氧基（1-4C）（1-4C）烷基，二[（1-4C）烷氧基]（1-4C）烷基，（羟基）[（1-4C）烷氧基]（1-4C）烷基;具有糖原磷酸化酶抑制活性，在治疗与增加的糖原磷酸化酶活性相关的疾病状态下，描述了制备含有它们的化合物和药物组合物的方法。

5. 发明申请

WO2005013975A1 INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有良好的磷酸酶抑制活性的吲哚胺衍生物
公开(公告)号：WO2005013975A1
公开(公告)日：2005-02-17
申请号：PCT/GB2004/003364
申请日：2004-08-04
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BIRCH, Alan, Martin , BENNETT, Stuart, Norman, Lile , GODFREY, Linda , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
发明人： BIRCH, Alan, Martin , BENNETT, Stuart, Norman, Lile , GODFREY, Linda , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
IPC分类号： A61K31/404
CPC分类号： C07D209/42
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt wherein, for example, A is phenylene or heteroarylene; Y is selected from -C(O)R 2 , -C(O)OR 2 , -C(O)NR 2 R 3 , -(1-4C)alkyl [optionally substituted] -(2-4C)alkenyl, -SO 2 NR 2 R 3 , and -S(O) C R 2 (wherein c is 0, 1 or 2); compounds which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐，其中例如A是亚苯基或亚杂芳基; Y选自-C（O）R 2，-C（O）OR 2，-C（O）NR 2 R 3， - （1-4C）烷基[任意取代的] （2-4C）烯基，-SO 2 NR 2 R 3和-S（O）CR 2（其中c为0,1或2）; 具有糖原磷酸化酶抑制活性的化合物，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备含有它们的化合物和药物组合物的方法。

6. 发明申请

WO2005020985A1 INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：具有良好的磷酸酶抑制活性的吲哚胺衍生物
公开(公告)号：WO2005020985A1
公开(公告)日：2005-03-10
申请号：PCT/GB2004/003620
申请日：2004-08-25
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
发明人： BENNETT, Stuart, Norman, Lile , SIMPSON, Iain
IPC分类号： A61K31/404
CPC分类号： C07D207/273 , C07D209/42 , C07D403/12 , C07D405/12 , C07D413/12
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; wherein: A is phenylene or heteroarylene; n is 0, 1 or 2; m is 0, 1 or 2; R' is for example selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, N-(1-4C)alkylcarbamoyl, N-(1-4C)alkylsulphamoyl, (1-4C)alkyl, (1-4C)alkoxy, (14C)alkanoyl, (1-4C)alkanoyloxy, hydroxy(1-4C)alkyl, fluoromethyl, and -NHSO2(14C)alkyl; or, when n is 2, the two R 1 groups, together with the carbon atoms of A to which they are attached, may form a 4 to 7 membered saturated ring, optionally containing 1 or 2 heteroatoms independently selected from 0, S and N; R 2 and R 3 together with the nitrogen to which they are attached form an optionally substituted 4- to 7-membered, heterocyclic ring; and R 4 is for example halo or (1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐或其前体药物; 其中：A是亚苯基或亚杂芳基; n为0,1或2; m为0,1或2; R 1选自卤素，硝基，氰基，羟基，羧基，氨基甲酰基，N-（1-4C）烷基氨基甲酰基，N-（1-4C）烷基氨磺酰基，（1-4C）烷基，（1-4C）烷氧基，（14C）烷酰基，（1-4C）烷酰氧基，羟基（1-4C）烷基，氟甲基和-NHSO2（14C）烷基; 或者当n为2时，两个R 1基团与它们连接的A的碳原子一起形成4至7元饱和的环，任选地含有1或2个独立地选自0，S 和N; R 2和R 3与它们所连接的氮一起形成任选取代的4-至7-元杂环; 和R 4是例如卤素或（1-4C）烷基; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备含有它们的化合物和药物组合物的方法。

7. 发明申请

WO2005019172A1 INDOL-2-AMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS 审中-公开
标题翻译：吲哚-2-酰胺作为GLYCOGEN磷酸酶抑制剂
公开(公告)号：WO2005019172A1
公开(公告)日：2005-03-03
申请号：PCT/GB2004/003552
申请日：2004-08-18
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BENNETT, Stuart, Norman, Lile , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
发明人： BENNETT, Stuart, Norman, Lile , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen
IPC分类号： C07D209/42
CPC分类号： C07D405/12 , C07D209/42
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example, R 4 is halo or (1-4C)alkyl ; A is phenylene or heteroarylene; n is 0, 1 or 2; m is 0, 1 or 2; R 1 is halo, cyano or carboxy; R 2 is for example methyl; R 3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐或其前体药物; （1）其中，例如，R 4为卤素或（1-4C）烷基; A是亚苯基或亚杂芳基; n为0,1或2; m为0,1或2; R 1是卤素，氰基或羧基; R 2例如是甲基; R 3例如选自卤素（1-4C）烷基，二卤代（1-4C）烷基，三氟甲基，羟基（1-4C）烷基，二羟基（2-4C）烷基，三羟基（3-4C）烷基，（1-4C）烷基（任选在羟基烷基上取代），（1-4C）烷氧基（1-4C）烷基，（1-4C）烷氧基（1-4C）烷氧基（1-4C）烷基，二（1-4C）烷氧基]（1-4C）烷基，（羟基）[（1-4C）烷氧基]（1-4C）烷基; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备含有它们的化合物和药物组合物的方法。

8. 发明申请

WO2005013981A1 HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY 审中-公开
标题翻译：杂环化合物酰胺衍生物，其具有磷酸酶抑制活性
公开(公告)号：WO2005013981A1
公开(公告)日：2005-02-17
申请号：PCT/GB2004/003345
申请日：2004-08-04
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BIRCH, Alan, Martin , BENNETT, Stuart, Norman, Lile , CAMPBELL, Andrew, Duncan , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen , WHALLEY, David, Paul , GODFREY, Linda
发明人： BIRCH, Alan, Martin , BENNETT, Stuart, Norman, Lile , CAMPBELL, Andrew, Duncan , SIMPSON, Iain , WHITTAMORE, Paul, Robert, Owen , WHALLEY, David, Paul , GODFREY, Linda
IPC分类号： A61K31/407
CPC分类号： C07D495/04
摘要： A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; wherein, for example, Z is CH or nitrogen, R 4 and R 5 together are either -S-C(R 6 )=C(R7)- or -C(R 7 )=C(R 6 )-S- ; R 6 and R 7 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy and carbamoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; r is 1 or 2; R 1 is halo, cyano or carboxy; Y is selected from -C(O)R 2 , -C(O)OR 2 , -C(O)NR 2 R 3 , -(1-4C)alkyl [optionally substituted] -(2-4C)alkenyl, -SO 2 NR 2 R 3 , and -S(O) c R 2 (wherein c is 0, 1 or 2); R 2 and R 3 are independently selected from hydrogen, -O(1-4C)alkyl, -S(1-4C)alkyl, -N(1-4C)alkyl, heterocyclyl, aryl, and (1-4C)alkyl [optionally substituted]; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
摘要翻译：式（1）的化合物或其药学上可接受的盐或其前体药物; 其中，例如，Z是CH或氮，R 4和R 5一起是-SC（R 6）= C（R 7） - 或-C（R 7）= C（R <6>） - S-; 氰基，羟基，氟甲基，二氟甲基，三氟甲基，三氟甲氧基，羧基和氨基甲酰基; R 6和R 7独立地选自氢，卤素，硝基，氰基，羟基， A是亚苯基或亚杂芳基; n为0,1或2; r为1或2; R 1是卤素，氰基或羧基; Y选自-C（O）R 2，-C（O）OR 2，-C（O）NR 2 R 3， - （1-4C）烷基[任意取代的] （2-4C）烯基，-SO 2 NR 2 R 3和-S（O）c R 2（其中c为0,1或2）; R 2和R 3独立地选自氢，-O（1-4C）烷基，-S（1-4C）烷基，-N（1-4C）烷基，杂环基，芳基和（1- 4C）烷基[任选取代的]; 具有糖原磷酸化酶抑制活性，因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。描述了制备含有它们的化合物和药物组合物的方法。

9. 发明申请

WO2010049731A1 PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS 审中-公开
标题翻译：作为IGF-1R酪氨酸激酶抑制剂的吡唑并 - 咪唑并吡啶并吡啶胺
公开(公告)号：WO2010049731A1
公开(公告)日：2010-05-06
申请号：PCT/GB2009/051447
申请日：2009-10-28
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , DUCRAY, Richard , JONES, Clifford, David , JUNG, Frédéric, Henri , SIMPSON, Iain
发明人： DUCRAY, Richard , JONES, Clifford, David , JUNG, Frédéric, Henri , SIMPSON, Iain
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04
摘要： There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
摘要翻译：提供式（I）的新型嘧啶衍生物或其药学上可接受的盐，其制备方法，含有它们的药物组合物及其在治疗中的用途。

10. 发明申请

WO2007135374A1 DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS 审中-公开
标题翻译：作为抗增生剂的二氢异喹啉化合物
公开(公告)号：WO2007135374A1
公开(公告)日：2007-11-29
申请号：PCT/GB2007/001806
申请日：2007-05-16
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , SIMPSON, Iain , WARD, Richard, Andrew
发明人： SIMPSON, Iain , WARD, Richard, Andrew
IPC分类号： C07D475/00
CPC分类号： C07D475/00
摘要： Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.
摘要翻译：描述了式（I）化合物或任选其药理学上可接受的酸加成盐，以及它们在抑制PLK活性中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式